Objective: Establish an educational “Master Class” program to prepare health care providers (HCPs) for CSAI availability in the U.S. and develop educational support for people with PD (PwPD) throughout all stages of CSAI use.

Background: CSAI (Onapgo™) received FDA approval in February 2025. To ensure clinician confidence in using CSAI and the best possible patient experience, Supernus Pharmaceuticals, Inc., collaborated with movement disorder specialists (MDS) to design a comprehensive “Master Class” for U.S. HCPs to gain knowledge and experience with its use. Additionally, recognizing the potential impact of PwPD and care partner (CP) education and support throughout CSAI use, a Clinical Nurse Navigator (CNN) program specific to CSAI will be offered to all PwPD who receive a prescription.

Method: Needs assessment was conducted with U.S. MDS, UK nurses experienced in CSAI therapy, the Apokyn CNN team, and PwPD survey data.  Course structure and content were drafted with MDS faculty. PwPD, CP, and HCP office support programs were designed with the CNN team.  Feedback mechanisms were incorporated into both programs for continual improvement.

Results: Based on needs assessment and advisor feedback, a Master Class program was designed to be delivered by MDS faculty with CSAI experience. Content consists of didactic training, clinical conversations with faculty regarding practical application of learnings to individual PwPD situations, and hands-on sessions to practice device programming, and understand medication ordering process and clinical services. The CNN educational program is delivered by registered nurses with PD expertise. CNNs primarily conduct in-home visits which include tailored education beginning pre-treatment and continuing throughout CSAI therapy. They also support in-clinic visits while HCPs incorporate CSAI into their practice.

Conclusion: The Master Class and CNN programs provide a framework for HCPs, PwPD, and CP to gain confidence and proficiency in using CSAI therapy and may contribute to improved knowledge and patient adherence. Learnings from these programs can be used to enhance healthcare delivery for PwPD.

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/establishing-clinical-education-and-patient-support-programs-for-continuous-subcutaneous-apomorphine-infusion-csai-in-the-united-states/